A study by the global analytics firm Evalueserve has found that patent applications in China are seven times higher than in India, a gap that will remain for at least five more years, which is all the more ironic, given that China is, at least nominally, governed by a Communist government. Although part of the reason for the gap is the more recent adoption by India of a patent protection system, the 2005 Patent Law (Marketletters passim), clear differences in business culture and government efficiency appear to be involved. The drug and chemical industries dominate Indian intellectual property rights claims.
Perhaps the most striking difference between the two Asian giants is the proportion of local firms filing patents: about 20% in India versus 62% in China. If people in India identify, with good reason, patents with the protection of foreign firms' IPRs, this runs the danger of making them appear less legitimate. Ram Deshpande, a senior manager of Evalueserve's Shanghai, China, office, told the Wall Street Journal's Livemint.com that "Indian companies are going to lose out in the long run."
One solution offered by the report is the creation of an intermediary form of utility model patents, which would be cheaper to file with the authorities, involve less scrutiny but offer exclusivity for only 10 years. The authors argue that such a scheme already operates successfully in China, Germany and Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze